Methenamine Hippurate Tablets Global Market Report 2024

The methenamine hippurate tablets market size has grown strongly in recent years. It will grow from $8.97 billion in 2023 to $9.63 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The expansion observed in the historical period can be attributed to factors such as traditional urinary tract infection (UTI) treatments, concerns related to antibiotic resistance, clinical validation of non-antibiotic solutions, patterns in physician prescriptions, and patient preferences for non-antibiotic approaches to UTI treatment.

The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $12.83 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to factors such as the increasing prevalence of urinary tract infections (UTIs), rising concerns about antibiotic resistance, advancements in UTI management, a healthcare focus on preventive therapies, and ongoing clinical trials and research. Major trends expected in the forecast period include an increase in UTI incidence, growing antibiotic resistance, a preference for non-antibiotic treatments, a focus on preventive healthcare measures, and continued research and development in the field.

The anticipated increase in the geriatric population is poised to drive the growth of the methenamine hippurate tablets market in the coming years. The geriatric population comprises individuals aged 60 and above, who are more susceptible to urinary tract infections due to factors such as reduced urine flow, enlarged prostate, or kidney stones. Consequently, the demand for methenamine hippurate tablets for treating these conditions is expected to rise. For instance, the World Health Organization reports that by 2030, one in six people worldwide will be 60 or older. In 2021, the global population of individuals aged 60 and older was 1.4 billion, projected to double by 2050 to reach 2.1 billion. The number of individuals aged 80 and older is expected to triple, reaching 426 million. Thus, the increasing geriatric population is a key driver for the growth of the methenamine hippurate tablets market.

The surge in urinary tract infection cases is anticipated to contribute to the growth of the methenamine hippurate tablets market. Urinary tract infections, resulting from bacteria entering the urethra and infecting the urinary tract, are common ailments. Methenamine hippurate tablets are crucial for preventing or treating recurrent urinary tract infections caused by specific bacteria. For instance, in 2021, Frontiers reported around 5,870 urine tests, with 2,070 of them yielding positive results, making up 35.26% of all urine tests. Consequently, the increasing prevalence of urinary tract infections is driving the growth of the methenamine hippurate tablets market.

A prominent trend in the methenamine hippurate tablets market is the emergence of product innovations. Major companies in the market are actively developing innovative products to enhance their market positions. For example, in August 2021, Custex, a US-based urinary health brand, introduced Cystex Ultra Protection. This product includes unique features such as probiotics, cranberries, vitamin A, and bio-shield technology. Cystex Ultra Protection is specifically designed to treat recurrent urinary tract infections and maintain urinary tract health in over 90% of women.

Strategic collaborations have become a significant avenue for major companies operating in the methenamine hippurate tablets market to enhance profitability. These collaborations involve purposeful partnerships between entities to achieve mutual goals through coordinated efforts, leveraging each other's strengths and resources. In May 2023, EQL Pharma AB, a Swedish pharmaceutical company providing methenamine hippurate tablets, entered into a collaboration with Dr. Pfleger Arzneimittel GmbH. Through this collaboration, EQL Pharma AB aims to launch Methenamine Hippurate with an EQL-registered brand within the next two years, involving standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price upon regulatory approval. Dr. Pfleger Arzneimittel GmbH is a German pharmaceutical company.

In April 2022, Aurelius Group, a German asset management company, acquired McKesson UK for an undisclosed amount. This acquisition is intended to support growth and development across retail, digital, homecare, and wholesale divisions, expanding the healthcare system to enhance patient outcomes. McKesson UK is a UK-based healthcare company providing methenamine hippurate tablets.

Major companies operating in the methenamine hippurate tablets market report are Validus Pharmaceuticals LLC, Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Edenbridge Pharmaceuticals LLC, Kreative Organics, CorePharma LLC, Amneal Pharmaceuticals Inc., Viatris Inc., County Line Pharmaceuticals, Mylan N.V., McKesson Corporation, Nuray Chemicals Private Limited, Chemische Fabrik Berg GmbH, Siegfried AG, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Ajanta Pharma Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Taro Pharmaceutical Industries Ltd., Sandoz International GmbH.

North America was the largest region in the methenamine hippurate tablets market in 2023. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methenamine hippurate tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of methenamine hippurate tablets are available in two forms, 20 tablets per bottle and 6 tablets per bottle. Patients can access methenamine hippurate tablets in the form of a 20-tablet bottle. These tablets are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The applications for these tablets include uncomplicated urinary tract infections (UTIs) and healthcare-associated UTIs. The end users encompass hospitals, homecare settings, specialty clinics, and others.

The methenamine hippurate tablets market research report is one of a series of new reports that provides methenamine hippurate tablets market statistics, including methenamine hippurate tablets industry global market size, regional shares, competitors with methenamine hippurate tablets market share, detailed methenamine hippurate tablets market segments, market trends, and opportunities, and any further data you may need to thrive in the methenamine hippurate tablets industry. This methenamine hippurate tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.